CurrentNeighborhood Health Plan of Rhode IslandPolicy 1887-A

Tobramycin Inhalation

Defines coverage criteria for tobramycin inhalation products (TOBI, TOBI Podhaler, Bethkis, Kitabis Pak and generics) for cystic fibrosis and non-cystic fibrosis bronchiectasis when Pseudomonas aeruginosa is present or previously documented; includes authorization durations and continuation criteria.

Policy Summary

PayerNeighborhood Health Plan of Rhode Island

PolicyTobramycin Inhalation

Policy CodePolicy 1887-A

Change TypeNo material changes

Effective Date

Next Review Date

Key ActionRequest authorization for up to 12 months when diagnosis and presence or history of Pseudomonas aeruginosa are documented; reauthorization requires evidence of benefit (disease stability or improvement).

SourceLink

POLICY UPDATE CHANGES

No material changes

2Covered Indications (CF and non-CF bronchiectasis)

12Authorization duration (months)

>=2Minimum age for CF indication

Other usesExperimental / Not medically necessary

Coverage Summary

Scope: This policy (Policy Number 1887-A) defines coverage for tobramycin inhalation products (solution and powder; branded and generic) for management of cystic fibrosis and for compendial use in non-cystic fibrosis bronchiectasis when Pseudomonas aeruginosa is present or previously documented. Coverage stance: covered_with_criteria. Other indications are considered experimental/investigational and not medically necessary.

Applicable Codes

Drugs referenced (brand and generic; all dosage forms/strengths)NDC|mixedCovered

TOBI	tobramycin inhalation solution (brand)
TOBI Podhaler	tobramycin inhalation powder (brand)
Bethkis	tobramycin inhalation solution (brand)
Kitabis Pak	tobramycin inhalation solution (brand)
Generic tobramycin inhalation	all generic formulations, forms, and strengths

Provider Actions / Prior Authorization

Prior Authorization

Authorization required

Authorization may be granted for up to 12 months when the applicable diagnosis and presence or history of Pseudomonas aeruginosa are documented; reauthorization requires evidence of benefit (disease stability or improvement).

Documentation Required

Microbiologic evidence or history required

Documentation must show Pseudomonas aeruginosa present in airway cultures OR a history of Pseudomonas aeruginosa infection or colonization in the airways for initial authorization.

Documentation Required

Clinical evidence for continuation

For reauthorization, documentation of disease stability or improvement while on therapy is required.

Clinical Evidence & Sources

Evidence sources: product package inserts for Tobramycin inhalation solution, TOBI, TOBI Podhaler, Bethkis, and Kitabis Pak, and compendia/guidelines including Lexicomp, the Cystic Fibrosis Foundation guidelines, European Respiratory Society (ERS) guidelines, and American College of Chest Physicians (ACCP) guidance. Coverage decisions are based on these indicated FDA and compendial uses.

Background

Background: Tobramycin inhalation products are FDA-indicated for management of cystic fibrosis in patients with Pseudomonas aeruginosa and are used compendially for Pseudomonas aeruginosa lower respiratory tract infection in patients with non-cystic fibrosis bronchiectasis. Coverage under this policy is limited to these indications with documented presence or history of Pseudomonas aeruginosa; all other uses are considered experimental/investigational and not medically necessary.

Quick facts

Covered indicationsCystic fibrosis with Pseudomonas aeruginosa; Non‑CF bronchiectasis with Pseudomonas aeruginosa

Authorization duration12 months

Minimum age for CF indication>= 2 years

Experimental / Not medically necessaryAll other uses (indications not listed above)

Revision History

Policy status: CURRENT. Policy Number: 1887-A. There are no documented policy changes (has_material_change = false). Effective date, last review date, and next review date are not specified.